Cytokinetics Faces Class Action Lawsuits Over Alleged Misstatements Regarding Aficamten Approval

### Cytokinetics Faces Class Action Lawsuits Over Alleged Regulatory Misstatements

Cytokinetics, Incorporated is embroiled in legal challenges as two law firms announce class action lawsuits on behalf of shareholders. The lawsuits allege violations of the Securities Exchange Act of 1934 concerning Cytokinetics’ communications about its New Drug Application (NDA) for aficamten. Investors who purchased Cytokinetics securities between December 27, 2023, and May 6, 2025, are encouraged to reach out to the firms before the November 17, 2025, deadline for filing claims. The crux of these allegations centers on claims that Cytokinetics misleadingly asserted that it expected FDA approval for aficamten in the latter half of 2025 while omitting critical information about the risks associated with its NDA submission.

The lawsuits highlight a significant oversight by Cytokinetics concerning the submission of a Risk Evaluation and Mitigation Strategy (REMS), which is a crucial component for FDA review. Despite multiple pre-NDA meetings with the FDA where safety and risk mitigation strategies were presumably discussed, Cytokinetics submitted its NDA without the necessary REMS. This omission raises serious concerns about the company’s public disclosures and has reportedly led to substantial financial losses for investors once the truth surrounding the NDA process came to light on May 6, 2025. The firms filing these lawsuits aim to hold Cytokinetics accountable for what they describe as materially misleading statements that could have influenced investor decisions.

In response to these developments, both the Schall Law Firm and DJS Law Group are actively seeking shareholders who believe they have been harmed by Cytokinetics’ actions. They stress that potential class members are not currently represented unless they take action to join the lawsuit. The emphasis is placed on the need for prompt action to ensure participation in any potential recovery efforts. By encouraging affected investors to come forward, these firms demonstrate their commitment to advocating for shareholder rights and corporate accountability within the pharmaceutical sector.

As litigation unfolds, Cytokinetics must navigate the implications of these lawsuits while maintaining its focus on advancing aficamten through the drug approval process. Investors and stakeholders will be closely monitoring the situation, particularly as the company addresses regulatory requirements and seeks to uphold its commitments to transparency and compliance in its operations.